HSBC set a €63.00 ($73.26) price objective on Bayer (FRA:BAYN) in a research report sent to investors on Wednesday, August 7th, Borsen Zeitung reports. The brokerage currently has a neutral rating on the healthcare company’s stock.
Other research analysts have also issued reports about the stock. Baader Bank set a €123.00 ($143.02) target price on shares of Bayer and gave the company a buy rating in a research note on Wednesday, August 7th. Independent Research set a €53.00 ($61.63) target price on shares of Bayer and gave the company a sell rating in a research note on Thursday, August 1st. Kepler Capital Markets set a €70.00 ($81.40) target price on shares of Bayer and gave the company a neutral rating in a research note on Thursday, June 27th. UBS Group set a €110.00 ($127.91) target price on shares of Bayer and gave the company a buy rating in a research note on Monday, August 5th. Finally, Barclays set a €85.00 ($98.84) target price on shares of Bayer and gave the company a buy rating in a research note on Tuesday, July 30th. One equities research analyst has rated the stock with a sell rating, eleven have assigned a hold rating and twelve have assigned a buy rating to the stock. Bayer has a consensus rating of Hold and an average price target of €80.57 ($93.68).
Bayer stock opened at €64.35 ($74.83) on Wednesday. Bayer has a 12-month low of €91.58 ($106.49) and a 12-month high of €123.82 ($143.98). The business’s fifty day moving average price is €59.42.
Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, Crop Science, and Animal Health segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.
Further Reading: What is an SEC Filing?
Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.